It has been found that CRAL is mainly located in the cytoplasm and sponges the endogenous miR-505, consequently increasing CYLD expression, suppressing AKT activation, and enhancing the sensitivity of gastric cancer cells to DDP in vitro and in vivo [125]. The gene discussed is CYLD; the disease is gastric cancer.